8-K 1 w11130e8vk.htm FORM 8-K e8vk
 

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 25, 2005
HUMAN GENOME SCIENCES, INC.
(Exact name of registrant as specified in its charter)
         
Delaware   0-022962   22-3178468
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)
         
  14200 Shady Grove Road, Rockville, Maryland
   20850-7464
  (Address of principal executive offices)
     (ZIP Code)
Registrant’s telephone number, including area code: (301) 309-8504
 
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
o
  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
    
o
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
    
o
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
    
o
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Section 2 – Financial Information
Item 2.02. Results of Operations and Financial Condition.
     On July 25, 2005, Human Genome Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2005. A copy of the release is furnished as Exhibit 99.1 to this Report on Form 8-K.
     The information in this section of this Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
Section 9 – Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits.
  99.1   Press Release dated July 25, 2005.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
             
    HUMAN GENOME SCIENCES, INC.    
 
            
      /s/ James H. Davis    
         
 
  Name:   James H. Davis, Ph.D.    
 
  Title:   Executive Vice President, General Counsel and Secretary    
Date: July 25, 2005

 

 

INDEX TO EXHIBITS
     
Exhibit No.   Description
Exhibit 99.1
  Press Release dated July 25, 2005.